Inflammation Research

, Volume 61, Issue 5, pp 511–520 | Cite as

Effects of 1,25-(OH)2D3 on the expressions of vitamin D receptor, STAT5 and cytoskeletal rearrangement in human monocytes incubated with sera from type 2 diabetes patients and diabetic nephropathy patients with uremia

  • MengXue Yang
  • ZhaoNan Shen
  • DanYan Chen
  • Hua GanEmail author
  • Qing Shen
  • Bo Yang
  • XiaoGang Du
Original Research Paper



To explore the effects of 1,25-(OH)2D3 and lipopolysaccharide (LPS) plus human recombinant interleukin-15 (IL-15) on expression of vitamin D receptor (VDR) and STAT5, and cytoskeletal rearrangement in human monocytes incubated with sera from type 2 diabetes (T2DM) patients and diabetic nephropathy (DN) patients with uremia.

Materials and methods

Peripheral sera were isolated from healthy volunteers (control group, T2DM patients and DN uremic non-dialysis patients). After incubation with or without 1,25(OH)2D3, THP-1 monocytes were treated with LPS plus IL-15 prior to the collection of cells and supernatants. VDR mRNA transcription was examined by RT-PCR, whilst THP-1 monocytic VDR, STAT5 and p-STAT5 expressions were investigated by Western blotting. Concentrations of IL-6 and monocyte chemoattractant protein-1 (MCP-1) in supernatants were assessed by ELISA. Immunofluorescence and a laser confocal microscopy was used to examine the expression of VDR and cytoskeletal proteins.


Compared to the normal control, LPS and IL-15 down-regulate monocytic VDR expression in T2DM patients and DN uremic patients, whilst with cytoskeletal rearrangement, they up-regulate p-STAT5 expression as well as IL-6 and MCP-1 activity. Such effects could be in part blocked by 1,25-(OH)2D3.


The above results suggest that the anti-inflammatory mechanism of 1,25-(OH)2D3 may be related to cytoskeletal proteins, VDR and STAT5 signaling pathway.


1,25-(OH)2D3 Type 2 diabetes mellitus Diabetic nephropathy Uremia Monocytes 



We thank Professor Qifu Li, Dr Lai Han and Wei Xue Tang, for their cooperation in patient collection and design of the study and data analysis. This study was supported in part by the outstanding doctoral dissertation fund of Chongqing Medical University. Supported by the Key Project of Chongqing Municipal Health Bureau (2010-1-16).


  1. 1.
    John C, Pickup Dphil, et al. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27(3):813–23.CrossRefGoogle Scholar
  2. 2.
    Guadalupe OM, Virginia LP, Oscar LF, et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol. 2010;21:763–72.CrossRefGoogle Scholar
  3. 3.
    Gang JK, Young SK, Sang YH, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant. 2008;23(9):2750–60.CrossRefGoogle Scholar
  4. 4.
    Juan F, Navarro G, Carmen MF, et al. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19(3):433–42.CrossRefGoogle Scholar
  5. 5.
    Morii T, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep. 2006;6(6):463–8.CrossRefGoogle Scholar
  6. 6.
    Navarro JF, Mora C. Diabetes, inflammation, proinflammatory cytokines, and diabetic nephropathy. Sci World J. 2006;6:908–17.CrossRefGoogle Scholar
  7. 7.
    Tuttle KR. Linking metabolism ang immunology:diabetic nephropathyis an inflammatory disease. J Am Soc Nephrol. 2005;16(6):1537–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Nathan C. Points of control in inflammation. Nature. 2002;420(6917):846–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Tracey KJ. The inflammatory reflex. Nature. 2002;420(6917):853–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Panichi V, Migliori M, Taccola D, et al. Effect s of 1,25(OH) 2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001;60:87–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Hypponen E, Boucher BJ, Berry DJ, et al. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross sectional study in the 1958 British Birth Cohort. Diabetes. 2008;57(2):298–305.PubMedCrossRefGoogle Scholar
  12. 12.
    Devaraj S, Yun JM, Catherine R, et al. Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am Soc Clin Pathol. 2011;135:429–33.CrossRefGoogle Scholar
  13. 13.
    Ozfirat Z, Chowdhury TA. Vitamin D deficiency and type 2 diabetes. Postgrad Med J. 2010;86:18–25.PubMedCrossRefGoogle Scholar
  14. 14.
    Kayaniyil S, Vieth R, et al. Association of vitamin D with insulin resistance and β-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care. 2010;33(6):1379–81.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamaoka K, Otsuka T, Niiro H, et al. Activation of STAT5 by lipopolysaccharide through granulocyte-macrophage colony-stimulating factor production in human monocytes. J Immunol. 1998;160(2):838–45.PubMedGoogle Scholar
  16. 16.
    Kimura A, Naka T, Muta T, et al. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK–STAT. PNAS. 2005;102(47):17089–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Musikacharoen T, Matsuguchi T, Kikuchi T, et al. NF-κB and STAT5 Play important roles in the regulation of mouse toll-like receptor 2 gene expression. J Immunol. 2001;166(7):4516–24.PubMedGoogle Scholar
  18. 18.
    Foster N, Lea SR, Preshaw PM, et al. Pivotal advance: Vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. J Leukoc Biol. 2007;81(4):893–903.PubMedCrossRefGoogle Scholar
  19. 19.
    Foster1 N, Andreadou K, Jamieson L, et al. VIP Inhibits P. gingivalis LPS-induced IL-18 and IL-18BPa in Monocytes. JDR. 2007;86(9):883–7.Google Scholar
  20. 20.
    Pelletier M, Girard D. Interleukin-15 increases neutrophil adhesion onto human respiratory epithelial A549 cells and attracts neutrophils in vivo. Clin Exp Immunol. 2005;141(2):315–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Girard D, Paquet ME, Paquin R, et al. Differential effects of interleukin-15 (IL-15) and IL-2 on human neutrophils: modulation of phagocytosis, cytoskeleton rearrangement, gene expression, and apoptosis by IL-15. Blood. 1996;88:3176–84.PubMedGoogle Scholar
  22. 22.
    Alleva DG, Kaser SB, Monroy MA, et al. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition. J Immunol. 1997;159:2941–51.PubMedGoogle Scholar
  23. 23.
    Tripathi P, Kurtulus S, Wojciechowski S, et al. STAT5 is critical to maintain effector CD8+ T cell responses. J Immunol. 2010;185:2116–24.PubMedCrossRefGoogle Scholar
  24. 24.
    Vidal M, Ramana CV, Dusso AS. Stat1-vitamin D receptor interactions antagonize 1,25-Dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol. 2002;22(8):2777–87.PubMedCrossRefGoogle Scholar
  25. 25.
    Stubbs JR, Idiculla A, Slusser J, et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21(2):353–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Rocky P, John RA, Christina L, et al. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol. 2004;232(2):137–43.CrossRefGoogle Scholar
  27. 27.
    Kambis S, Barbara W, Ute L, et al. Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006;36:361–70.CrossRefGoogle Scholar
  28. 28.
    Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50(11):2374–83.PubMedCrossRefGoogle Scholar
  30. 30.
    Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia induced inflammation in high fat diet induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81.PubMedCrossRefGoogle Scholar
  31. 31.
    Burcelin R, Luche E, Serino M, et al. The gut microbiota ecology:a new opportunity for the treatment of metabolic diseases? Front Biosci. 2009;14:5107–17.PubMedCrossRefGoogle Scholar
  32. 32.
    Vrieze A, Holleman F, Zoetendal EG, et al. The environment within: how gut microbiota, may influence_metabolism and boay composition. Diabetologia. 2010;53(4):606–13.PubMedCrossRefGoogle Scholar
  33. 33.
    Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292(3):E740–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Pramanik R, Asplin JR, Lindeman C, et al. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells. Cell Immunol. 2004;232(1–2):137–43.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 2012

Authors and Affiliations

  • MengXue Yang
    • 1
    • 2
  • ZhaoNan Shen
    • 3
  • DanYan Chen
    • 1
  • Hua Gan
    • 1
    Email author
  • Qing Shen
    • 1
  • Bo Yang
    • 2
  • XiaoGang Du
    • 1
  1. 1.Department of NephrologyFirst Affiliated Hospital of ChongQing Medical UniversityChongQingChina
  2. 2.First Affiliated Hospital of Zun Yi Medical CollegeZunYiChina
  3. 3.The Fifth People’s Hospital of ChongQingChongQingChina

Personalised recommendations